Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis (NYSE:LLY)

- In pivotal studies, most patients treated with Taltz achieved significant skin clearance (PASI 75, sPGA 0 or 1) with many achieving virtually clear (PASI 90) or completely clear (PASI 100, sPGA 0) skin at week 12 -

Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis (NYSE:LLY)